Leuprorelin Acetate in Prostate Cancer: A European Update

Persad, Rajendra

doi:10.1111/j.1742-1241.2002.tb11280.x

Cited by 21 publications

(3 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Testosterone suppression via ADT in treatment of advanced prostate cancer has several benefits compared with surgical castration, including reversibility and lack of surgical complications 4 . LA formulations have evolved in ongoing efforts to provide convenient, long‐term testosterone suppression for these patients 5 . However, this diversity in formulation may result in substantial differences impacting the clinical practice such as time needed to reconstitute and administer the product.…”

Section: Discussionmentioning

confidence: 99%

“…4 LA formulations have evolved in ongoing efforts to provide convenient, long-term testosterone suppression for these patients. 5 However, this diversity in formulation may result in substantial differences impacting the clinical practice such as time needed to reconstitute and administer the product.…”

Section: Discussionmentioning

confidence: 99%

“…Leuprolide acetate (LA) is a potent gonadotropin-releasing hormone agonist used as androgen deprivation therapy (ADT) in the treatment of prostate cancer. [1][2][3][4][5] Current formulations of LA include LA for depot suspension (Lupron Depot, IM-LA), which is administered intramuscularly, and LA (Eligard, SC-LA), which is administered subcutaneously. 6,7 Both IM-LA and SC-LA are administered over a 1-, 3-, 4-, or 6-month treatment period, and both must be reconstituted prior to administration.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Preparation and administration of androgen deprivation therapy products: Retrospective survey results

Goldfischer¹,

Grubb

Nisbet³

2023

Int J of Uro Nursing

View full text Add to dashboard Cite

Leuprolide acetate (LA) is a gonadotropin‐releasing hormone agonist used as androgen deprivation therapy for advanced prostate cancer. LA is available in formulations intended for intramuscular (IM‐LA) or subcutaneous (SC‐LA) administration. Post‐marketing reports have noted handling errors associated with the preparation and administration of SC‐LA. This study gathered real‐world evidence on administration and management of IM‐LA and SC‐LA in large, urology‐ or oncology‐based practices. Over 200 staff were invited; 151 participated in an online survey. Main outcomes were time for each step of the ordering, inventory, mixing and administration processes. Mean values and standard errors are reported for continuous variables, and frequency and percentage are reported for categorical variables. Comparisons between groups were made with t tests and chi‐square tests as appropriate. For IM‐LA and SC‐LA, ease of ordering and time to place an order (10.8 ± 1.3 vs. 10.6 ± 1.4 min, respectively) were similar. IM‐LA was associated with a shorter time to complete preparation (2.5 ± 0.2 vs. 6.1 ± 0.6 min, P < 0.001) compared with SC‐LA. This difference of 3.6 min per preparation could result in substantial time savings annually ranging from 120 h per year to 240 h per year in clinical practices administering 2000 injections per year or 4000 injections per year, respectively. For IM‐LA vs. SC‐LA, greater ease of preparation was reported by 64% vs. 43% of respondents, respectively. Over 15% of respondents used injection sites inconsistent with prescribing information, regardless of the type of injection. This study found that it takes a significantly shorter time to prepare and administer IM‐LA than SC‐LA in large urology‐ and oncology‐based practices. The time saved could be utilized for other tasks such as seeing additional patients. Use of injection sites inconsistent with prescribing information suggests a need for more training of nursing staff in the proper administration of these drugs to ensure adequate testosterone suppression and patient safety.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preparation and administration of androgen deprivation therapy products: Retrospective survey results

Goldfischer¹,

Grubb

Nisbet³

2023

Int J of Uro Nursing

View full text Add to dashboard Cite

show abstract

Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer

See

2003

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Prostate cancer is being diagnosed at an earlier age and earlier disease stage than previously and increasing numbers of relatively young men are receiving potentially curative radical prostatectomy or radiotherapy for early prostate cancer. Although many of these men have an excellent outcome, a significant proportion subsequently experience disease recurrence or cancer-related death. Men with unfavorable tumor characteristics at the time of radical prostatectomy or radiotherapy are particularly at high risk of experiencing disease recurrence. One strategy to improve outcome for these men is adjuvant hormone therapy (hormone therapy administered immediately after therapy of primary curative intent). Surgical castration (bilateral orchiectomy), medical castration using the luteinizing hormone-releasing hormone (LHRH) agonist goserelin, and antiandrogen monotherapy have been investigated as adjuvant hormone therapy to radical prostatectomy and radiotherapy, and each therapy has demonstrated clinical benefits because of a significant improvement in disease-free survival. Furthermore, data are available to indicate that adjuvant hormone therapy achieved by goserelin or bilateral orchiectomy improves overall survival, particularly in men at high risk of progression. Because the effects of LHRH agonists are reversible, they provide a more acceptable method of adjuvant therapy compared to bilateral orchiectomy, particularly in the adjuvant setting, and are preferred by patients. However, the adverse effects on quality of life, in particular on sexual interest and function and bone mineral density, may limit the use of LHRH agonists in some patients. However, these parameters are maintained with nonsteroidal antiandrogens. The first data from the Early Prostate Cancer program indicate that adjuvant bicalutamide 150 mg is associated with a significant improvement in progression-free survival after radical prostatectomy or radiotherapy. Gynecomastia and breast pain are the most common side effects associated with bicalutamide therapy. Medical or surgical castration in combination with an antiandrogen (combined androgen blockade) is another option for use as an adjuvant hormone therapy. However, no study has reported on the use of combined androgen blockade in this setting. Adjuvant hormone therapy provides clinicians with another treatment option for patients with early prostate cancer and unfavorable tumor characteristics.

show abstract

Patient rationale in selecting androgen deprivation (PRISAD): do we give patients what they want?

et al. 2008

View full text Add to dashboard Cite

To assess patient rationale in selecting androgen deprivation, structured telephone interviews were conducted on consecutive patients on androgen deprivation over a 17-year period. The majority of these patients have stable disease that require long-term follow-up with 6-monthly PSA estimations. Synchronous PSA check with depot injections are preferred by majority of patients and longer intervals between the depot administrations are preferable due to perceived less needle pain. This study highlights for the first time patients' preferences for synchronous PSA check with their depot injections and a longer interval between the depot administrations due to perceived less needle pain.

show abstract

Leuprorelin Acetate in Prostate Cancer: A European Update

Cited by 21 publications

References 76 publications

Preparation and administration of androgen deprivation therapy products: Retrospective survey results

Preparation and administration of androgen deprivation therapy products: Retrospective survey results

Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer

Patient rationale in selecting androgen deprivation (PRISAD): do we give patients what they want?

Contact Info

Product

Resources

About